![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 25, 26314-26322, June 18, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


¶

**
From the
Department of Neuroscience, Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada and ¶Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario N6A 5C1, Canada
To identify novel regulators of G
o, the most abundant G-protein in brain, we used yeast two-hybrid screening with constitutively active G
o as bait and identified a new regulator of G-protein signaling (RGS) protein, RGS17 (RGSZ2), as a novel human member of the RZ (or A) subfamily of RGS proteins. RGS17 contains an amino-terminal cysteine-rich motif and a carboxyl-terminal RGS domain with highest homology to hRGSZ1- and hRGS-G
-interacting protein. RGS17 RNA was strongly expressed as multiple species in cerebellum and other brain regions. The interactions between hRGS17 and active forms of G
i13, G
o, G
z, or G
q but not G
s were detected by yeast two-hybrid assay, in vitro pull-down assay, and co-immunoprecipitation studies. Recombinant RGS17 acted as a GTPase-activating protein (GAP) on free G
i2 and G
o under pre-steady-state conditions, and on M2-muscarinic receptor-activated G
i1, G
i2, G
i3, G
z, and G
o in steady-state GTPase assays in vitro. Unlike RGSZ1, which is highly selective for Gz, RGS17 exhibited limited selectivity for Go among Gi/Go proteins. All RZ family members reduced dopamine-D2/G
i-mediated inhibition of cAMP formation and abolished thyrotropin-releasing hormone receptor/G
q-mediated calcium mobilization. RGS17 is a new RZ member that preferentially inhibits receptor signaling via Gi/o, Gz, and Gq over Gs to enhance cAMP-dependent signaling and inhibit calcium signaling. Differences observed between in vitro GAP assays and whole-cell signaling suggest additional determinants of the G-protein specificity of RGS GAP effects that could include receptors and effectors.
Received for publication, February 18, 2004 , and in revised form, April 9, 2004.
* This research was supported by grants from the Ontario Mental Health Foundation (to P. R. A.) and the Canadian Institutes of Health Research (to P. R. A. and P. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Both authors contributed equally to this work.
|| To whom correspondence should be addressed. Tel.: 519-661-3318; Fax: 519-661-3827; E-mail: peter.chidiac{at}fmd.uwo.ca. ** To whom correspondence should be addressed. Tel.: 613-562-5800, ext. 8307; Fax: 613-562-5403; E-mail: palbert{at}uottawa.ca.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. E. Feigin and C. C. Malbon RGS19 regulates Wnt beta-catenin signaling through inactivation of G{alpha}o J. Cell Sci., October 1, 2007; 120(19): 3404 - 3414. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Garzon, M. Rodriguez-Munoz, A. Lopez-Fando, and P. Sanchez-Blazquez Activation of {micro}-Opioid Receptors Transfers Control of G{alpha} Subunits to the Regulator of G-protein Signaling RGS9-2: ROLE IN RECEPTOR DESENSITIZATION J. Biol. Chem., March 11, 2005; 280(10): 8951 - 8960. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hahn, T. K. Bera, K. Gehlhaus, I. R. Kirsch, I. H. Pastan, and B. Lee Finding fusion genes resulting from chromosome rearrangement by analyzing the expressed sequence databases PNAS, September 7, 2004; 101(36): 13257 - 13261. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |